Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > November 8, 2022
Daily News
November 8, 2022
- Eisai’s H1 Operating Profit Tanks 91.3% over Pullback from BMS Alliance Gain
November 8, 2022
- MOF Panel Member Calls for Drug Price Cuts to Unleash Innovation, Ease Household Burdens
November 8, 2022
- Eisai Divests Rights to Myonal, Merislon to Swiss Firm DKSH
November 8, 2022
- Japan Panel Recognizes 6 More Deaths Possibly Linked to COVID Vaccines
November 8, 2022
- MOF Proposes Transition to Normal Framework for COVID Vaccines, Therapeutics
November 8, 2022
- Eisai Begins Talks with US, EU, Japan Regulators towards Lecanemab Submissions; CMS Discussion Now Underway
November 8, 2022
- MOF Renews Its Push for Full Drug Price Revision in FY2023
November 8, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…